Comparison
Lanreotid vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
108736-35-2
80714-61-0
Molecular weight
1096.34 g/mol
813.92 g/mol
Half-life
no data
0.3 h
Sequence
no data
Met-Glu-His-Phe-Pro-Gly-ProMechanism of action
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
1
4
of which in humans
1
2
Effects recorded
2
3
Open conflicts
1
1
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Lanreotid and Semax?
- Lanreotid is classified as "Research other", while Semax is classified as "Research other". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Semax?
- The highest available evidence level is "Human RCT" for Lanreotid and "Human trial" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Semax in Germany and the United States?
- Germany: Lanreotid — Prescription, Semax — Unapproved. United States: Lanreotid — Prescription, Semax — Unapproved. These are factual summaries with source and review date on the individual pages.